Aurora Cannabis Set to Launch U.S. Market Entry Within Months: CCO

Aurora Cannabis Inc. (ACB), a top-tier global cannabis producer, is actively preparing to enter the lucrative U.S. CBD sector.

In a recent discussion with Business Insider, Cam Battley, Aurora's Chief Corporate Officer, shared that the company will soon disclose its roadmap to expand into the American market. Aurora stands as one of the largest publicly traded marijuana cultivators worldwide.

"Our hemp-derived CBD market entry strategy for the U.S. will be unveiled in the coming months," Battley stated. He withheld additional specifics, suggesting investors await Aurora’s Q2 earnings report scheduled for February 11 for comprehensive insights.

Significant Growth Potential Amid Legal Complexities

CBD, or cannabidiol, is a prominent compound extracted from cannabis plants, celebrated for its therapeutic benefits. It is reputed to alleviate conditions such as anxiety, eczema, depression, insomnia, and pain without inducing psychoactive effects. These attributes have propelled CBD’s integration into food and beverage products, with analysts forecasting substantial market expansion.

Vivien Azer, an analyst at Cowen investment bank, forecasts the U.S. CBD industry could reach $1.6 billion within the next year. Additionally, Brightfield Group, an authority in cannabis market intelligence, estimates the U.S. hemp-derived CBD market could soar to $22 billion by 2022.

While Aurora’s ambitions align with this booming market, legal hurdles persist. Despite legalization of marijuana in 33 U.S. states in various forms, the Drug Enforcement Administration continues to classify CBD as a Schedule I substance federally.

Even after the 2018 Farm Bill legalized hemp (a CBD source), the Food and Drug Administration maintains that adding CBD to food or health products remains illegal without its approval. This regulatory ambiguity has led many Canadian cannabis producers to hesitate in entering the U.S. market.

In a related development, Canopy Growth Corporation (CGC) recently secured a license from New York State to cultivate and process hemp, signaling growing industry momentum.

Strategic Acquisition: Whistler Medical Marijuana

Alongside its U.S. market entry plans, Aurora announced the acquisition of Whistler Medical Marijuana, a British Columbia-based company, for approximately $175 million.

Whistler is renowned as one of Canada’s first licensed producers to achieve organic certification, boasting strong brand recognition and premium pricing in both medical and retail sectors.

Aurora CEO Terry Booth emphasized the strategic value of this acquisition: "This deal brings an iconic, organically certified BC brand with impressive market traction and premium positioning. We plan to expedite Whistler’s Pemberton facility expansion and utilize our extensive domestic and international distribution networks to amplify their product reach."

Discover engaging topics and analytical content in Company News as of 20-01-2019. The article titled " Aurora Cannabis Set to Launch U.S. Market Entry Within Months: CCO " provides new insights and practical guidance in the Company News field. Each topic is meticulously analyzed to deliver actionable information to readers.

The topic " Aurora Cannabis Set to Launch U.S. Market Entry Within Months: CCO " helps you make smarter decisions within the Company News category. All topics on our website are unique and offer valuable content for our audience.